2 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 2 | Recruiting 1, Withdrawn 1 |
Follow Locally Advanced or Metastatic Urothelial Carcinoma: new trials by email Literature Review of Locally Advanced or Metastatic Urothelial Carcinoma trials Research Report on Locally Advanced or Metastatic Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma SHR-A2102 and Adebrelimab, Gemcitabine and cisplatin / carboplatin - Locally Advanced or Metastatic Urothelial Carcinoma | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 453 | 2026-02-12 | 2026-08-14 |
| A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer Metastatic Urothelial Carcinoma, Urothelial Cancer | Completed | Pfizer | 1 | 2026-02-12 | 2026-05-28 | |
| Neurological Function in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin-Based Therapy Neurological function assessment - Locally Advanced or Metastatic Urothelial Carcinoma | Not yet recruiting | National Taiwan University Hospital | 100 | 2025-07-01 | 2025-07-18 | |
| A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma Toripalimab Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection / Carboplatin Injection - Locally Advanced or Metastatic Urothelial Carcinoma | Phase 3 | Withdrawn | Shanghai Junshi Bioscience Co., Ltd. | 2022-09-06 | 2026-07-09 | |
| A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) Avelumab, Sacituzumab Govitecan (SG), M6223 - Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2 | Active not recruiting | EMD Serono Research & Development Institute, Inc. | 256 | 2022-08-17 | 2026-09-28 |
| Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma Atezolizumab 1200 mg/m2, Gemcitabine 1000 mg/m2, Cisplatin 70 mg/m2 - Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2 | Completed | Spanish Oncology Genito-Urinary Group | 82 | 2020-12-23 | 2025-04-24 |
Carcinoma, Transitional Cell (6) · Neoplasm Metastasis (1) · Neoplasms (1) · Urinary Bladder Neoplasms (1)
Carcinoma (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms (5) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Male Urogenital Diseases (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Urinary Bladder Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Urologic Diseases (1)
Cisplatin (3) · Gemcitabine (3) · Carboplatin (2) · Injections (1) · NKTR-255 (1) · atezolizumab (1) · avelumab (1) · sacituzumab govitecan (1) · toripalimab (1)
EMD Serono Research & Development Institute, Inc. (1) · National Taiwan University Hospital (1) · Pfizer (1) · Shanghai Junshi Bioscience Co., Ltd. (1) · Spanish Oncology Genito-Urinary Group (1) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1)
China (2) · Spain (2) · Taiwan (2) · United States (2) · Australia (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · South Korea (1) · United Kingdom (1)
Guillermo Velasco, M.D., Ph.D. (1)
2023 (1)